title: Thinking out of the box--new approaches to controlling GVHD.
abstract: Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic cell transplantation (allo-HCT). Despite major advances in the understanding of GVHD pathogenesis, standard GVHD prophylaxis regimens continue to be based on the combination of a calcineurin inhibitor with an antimetabolite, while first line treatments still rely on high-dose corticosteroids. Further, no second line treatment has emerged thus far in acute or chronic GVHD patients who failed to respond with corticosteroid treatment. After briefly reviewing current standards of GVHD prevention and treatment, this article will discuss recent approaches that might change GVHD prophylaxis/treatment for decades to come, with a special focus on recently developed immunoregulatory strategies based on infusion of mesenchymal stromal or regulatory T-cells, or injection of low-dose interleukin-2.
authors.affiliation: Department of Medicine, Division of Hematology, University and CHU of Liège, Liège, Belgium, f.baron@ulg.ac.be.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Baron
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Humblet-Baron
authors.forename: Grégory
authors.initials: G
authors.lastname: Ehx
authors.forename: Sophie
authors.initials: S
authors.lastname: Servais
authors.forename: Muriel
authors.initials: M
authors.lastname: Hannon
authors.forename: Ludovic
authors.initials: L
authors.lastname: Belle
authors.forename: Chantal
authors.initials: C
authors.lastname: Lechanteur
authors.forename: Alexandra
authors.initials: A
authors.lastname: Briquet
authors.forename: Olivier
authors.initials: O
authors.lastname: Giet
authors.forename: Etienne
authors.initials: E
authors.lastname: Baudoux
authors.forename: Evelyne
authors.initials: E
authors.lastname: Willems
authors.forename: Yves
authors.initials: Y
authors.lastname: Beguin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents